125 related articles for article (PubMed ID: 28881784)
1. Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.
Soung YH; Kashyap T; Nguyen T; Yadav G; Chang H; Landesman Y; Chung J
Oncotarget; 2017 Aug; 8(32):52935-52947. PubMed ID: 28881784
[TBL] [Abstract][Full Text] [Related]
2. The Role of Arrestin Domain-Containing 3 in Regulating Endocytic Recycling and Extracellular Vesicle Sorting of Integrin β4 in Breast Cancer.
Soung YH; Ford S; Yan C; Chung J
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30545011
[TBL] [Abstract][Full Text] [Related]
3. Arrestin Domain Containing 3 Reverses Epithelial to Mesenchymal Transition and Chemo-Resistance of TNBC Cells by Up-Regulating Expression of miR-200b.
Soung YH; Chung H; Yan C; Ju J; Chung J
Cells; 2019 Jul; 8(7):. PubMed ID: 31295851
[TBL] [Abstract][Full Text] [Related]
4. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
[TBL] [Abstract][Full Text] [Related]
6. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
7. Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Marijon H; Gery S; Chang H; Landesman Y; Shacham S; Lee DH; de Gramont A; Koeffler HP
Oncotarget; 2021 Aug; 12(18):1749-1762. PubMed ID: 34504648
[TBL] [Abstract][Full Text] [Related]
8. XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.
Crochiere ML; Hannus S; Hansen K; Becker F; Baloglu E; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2017 Dec; 8(66):110503-110516. PubMed ID: 29299164
[TBL] [Abstract][Full Text] [Related]
9. α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis.
Arakaki AKS; Pan WA; Wedegaertner H; Roca-Mercado I; Chinn L; Gujral TS; Trejo J
J Cell Sci; 2021 Apr; 134(8):. PubMed ID: 33722977
[TBL] [Abstract][Full Text] [Related]
10. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
Shafique M; Ismail-Khan R; Extermann M; Sullivan D; Goodridge D; Boulware D; Hogue D; Soliman H; Khong H; Han HS
Oncologist; 2019 Jul; 24(7):887-e416. PubMed ID: 30996012
[TBL] [Abstract][Full Text] [Related]
12. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
Gravina GL; Mancini A; Sanita P; Vitale F; Marampon F; Ventura L; Landesman Y; McCauley D; Kauffman M; Shacham S; Festuccia C
BMC Cancer; 2015 Dec; 15():941. PubMed ID: 26620414
[TBL] [Abstract][Full Text] [Related]
13. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Martini S; Figini M; Croce A; Frigerio B; Pennati M; Gianni AM; De Marco C; Daidone MG; Argueta C; Landesman Y; Zaffaroni N; Satta A
Cells; 2020 Oct; 9(10):. PubMed ID: 33023194
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
15. Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.
Wu H; Bi J; Peng Y; Huo L; Yu X; Yang Z; Zhou Y; Qin L; Xu Y; Liao L; Xie Y; Conneely OM; Jonkers J; Xu J
Oncotarget; 2017 Aug; 8(33):54364-54377. PubMed ID: 28903348
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
17. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
Gravina GL; Mancini A; Colapietro A; Marampon F; Sferra R; Pompili S; Biordi LA; Iorio R; Flati V; Argueta C; Landesman Y; Kauffman M; Shacham S; Festuccia C
Oncotarget; 2017 Dec; 8(67):111225-111245. PubMed ID: 29340049
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
20. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways.
Benatar T; Yang W; Amemiya Y; Evdokimova V; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2012 Jun; 133(2):563-73. PubMed ID: 21997538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
